Home > Science > Secondary Progressive MS – Majority MS patients progress to SPMS indicating huge market potential

Secondary Progressive MS – Majority MS patients progress to SPMS indicating huge market potential

Added: (Sat Feb 17 2018)

Pressbox (Press Release) - Multiple Sclerosis is an autoimmune disorder that happens in the Central nervous system of the body. Multiple Sclerosis involves the brain, optic nerves and the spinal cord and leads to the destruction of the insulation layer, Myelin, which covers the nerve fibers in the CNS.

SPMS is characterized by a continuous increase in disability and worsening of symptoms with or without the period of relapses and remissions. As per the latest report by Pharmascroll, SPMS- A Detailed Overview, nearly 50% of RRMS patients progress to SPMS in a 10 year time period. In SPMS, the patients might not have relapses at all but the symptoms may not completely go off (plateau) in the remission period.

As per the current scenario in Multiple Sclerosis indication, there are over 15 molecules approved in the worldwide market. However, majority of the molecules are approved in the Relapsing Remitting form of Multiple Sclerosis. The more progressive forms of Multiple Sclerosis like Secondary Progressive MS and Primary progressive MS are still to encounter the boom in terms of number of launched molecules and hence the indication sales revenue.

However, as per the report SPMS- A Detailed Overview, for Secondary progressive MS, the scenario is changing rapidly. The usage of existing products like Tysabri, Ocrelizumab and Zinbryta in SPMS, expected launch of Siponimod by Novartis in SPMS segment in 2019 and a strong pipeline in progressive MS including the products Laquinimod by Teva, Masitinib by AB Sciences, Ponesimod by Actelion and Lemtrada by Sanofi, indicates a huge paradigm shift for the progressive forms of MS specifically SPMS.

The report provides an overview of SPMS in detail, highlights the SPMS epidemiology in the key geographies (Forecast to 2024), elaborates on the drugs prescribed and expected to be prescribed in SPMS and covers the detailed market sizing drug wise and country wise in value sales and patient numbers along with forecasts till 2030.

Why Purchase the report:
The report would help the pharma companies understand the SPMS indication in detail, identify business opportunities for making short term and long term plans, understand the epidemiology of SPMS, identify the triggers of prescription for the physicians in SPMS and make companies aware of the existing and upcoming competition along with their expected sales revenues and patient numbers in key geographies.

Companies Covered:
Biogen
Novartis
Sanofi Genzyme
Active Biotech
Merck
Teva
Bayer
Actelion
Medday Pharmaceuticals
Santhera Pharmaceuticals
AB Sciences
Roche
Genentech
Medicinova

Geographies covered:
US
Germany
France
Italy
Spain
UK
Japan
Australia
Canada

Table of Content:
1. Multiple Sclerosis Definition
2. Types of MS
a. RRMS
b. SPMS
c. PPMS
d. PRMS
3. SPMS defined
4. Causes of SPMS
5. Profile of SPMS Patient
6. Symptoms of SPMS
7. Disease progression and impact on QoL
8. Disease Diagnosis
a. Disease diagnosis through symptoms
b. Disease diagnosis through medical tests
9. Disease Epidemiology in US, UK, Germany, Italy, France, Spain, Japan
10. Factors impacting a physician’s prescription decision
a. Efficacy
b. Tolerability and Safety
c. Monitoring Requirements
d. Pricing and Reimbursement
11.Disease Modifying Therapies for SPMS
a. Laquinimod
b. Ocrelizumab
c. Masitinib
d. Lemtrada
e. Tysabri
f. Siponimod
g. Zinbryta
h. Mitoxantrone
i. Ponesimod
12.Drug Attribute Analysis
13. Other Pipeline Products
14. SPMS Market Sizing
a. Brand wise sales and patient numbers worldwide
b. Brand wise value and patient numbers by key geographies/countries
c. Country wise value sales and patient shares for all brands

The report can be checked at www.pharmascroll.com/product/spms-detailed-overview

Submitted by:Pharmascroll
Disclaimer: Pressbox disclaims any inaccuracies in the content contained in these releases. If you would like a release removed please send an email to remove@pressbox.co.uk together with the url of the release.